Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Slovenia Pharmaceuticals And Healthcare
Industry SWOT — 6
Slovenia Political
SWOT — 7
Slovenia Economic SWOT — 8
Slovenia Business SWOT — 8
Pharmaceutical Business
Environment Ratings — 9
Table: Emerging Europe –
Regional Pharmaceutical Business Environment Ratings for
Q409 — 9
Limits of Potential
Returns — 10
Risks to Realisation of
Returns — 10
Slovenia - Market
Summary — 12
Regulatory Regime — 13
Recent EU-Wide Regulatory Developments — 14
Intellectual
Property Regime — 15
IP
Deficiencies — 15
Pricing System — 17
Reimbursement Policies — 18
Eurozone
Entry — 19
Industry Developments — 21
Epidemiology — 21
Table: Disease Burden In
CEE — 23
Healthcare Sector — 24
Healthcare Provision Developments — 24
Healthcare
Insurance — 24
Healthcare
Expenditure — 26
Pharmaceutical
Industry — 26
Clinical Trials — 28
Medical Devices — 29
Industry Forecast
Scenario — 30
Overall Market
Forecast — 30
Table: Pharmaceutical Market Forecast
2004-2013 — 31
Key Growth Factors –
Industry — 32
Table: Healthcare Expenditure Forecast,
2004-2013 — 33
Key Growth Factors –
Macroeconomic — 34
Prescription Market
Forecast — 36
Table: Prescription Drug Market Forecast
2004-2013 — 37
Patented Market
Forecast — 38
Table: Patented Product Market Forecast
2004-2013 — 39
Generics Markets
Forecast — 40
Table: Generic Drug Market Forecast
2004-2013 — 40
OTC Market
Forecasts — 41
Table: OTC Medicine Market Forecast
2004-2013 — 42
Pharmaceutical Trade
Forecasts — 43
Table: Pharmaceutical Trade Forecast
(US$mn), 2004-2013 — 44
Other Healthcare Data
Forecasts — 45
Table: Other Healthcare Data Forecasts,
2004-2013 — 45
Key Risks to BMI’s Forecast
Scenario — 46
Competitive
Landscape — 47
Table: Leading Companies In Slovenia.
2007 — 47
Company Monitor — 48
Multinational Company Profiles — 48
GlaxoSmithKline — 48
Sanofi-Aventis — 50
Pfizer — 51
Novartis — 53
Merck & Co — 55
Indigenous Company Profiles — 57
Krka — 57
Lek (Novartis/Sandoz) — 62
Country Snapshot: Slovenia Demographic Data — 65
Section
1: Population — 65
Table: Demographic Indicators,
2005-2030 — 65
Table: Rural/Urban Breakdown,
2005-2030 — 66
Section 2: Education and
Healthcare — 66
Table: Education,
2002-2005 — 66
Table: Vital Statistics,
2005-2030 — 66
Section 3: Labour Market and Spending
Power — 67
Table: Employment Indicators,
2001-2006 — 67
Table: Consumer Expenditure, 2000-2012
(US$) — 67
Table: Average Annual Wages,
2000-2012 — 68
BMI Forecast
Modelling — 69
How We Generate Our Pharmaceutical Industry
Forecasts — 69
Pharmaceutical Business Environment Ratings
Methodology — 70
Ratings Overview — 70
Table: Pharmaceutical Business Environment Indicators — 71
Weighting — 72
Table: Weighting Of
Components — 72
Sources — 72
| 
View Cart
